Vilobelimab clinical trials
Vilobelimab is named as an intervention in 2 current clinical trials in our USA register. 2 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is PPD Development, LP. The most-studied condition is Acute Respiratory Distress Syndrome (ARDS).
Where Vilobelimab is approved
All regulators →Of the three regulators tracked here, the first to approve Vilobelimab was the EU, on 13 Jan 2025.
- 1 EU orphan designation, most recently for treatment of pyoderma gangrenosum (18 Jul 2022, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Vilobelimab works
All drug targets →- Complement C5 inhibitor InhibitorTarget: C5 complement C5ChEMBL only
- PyodermaPhase 3
- PneumoniaPhase 2/3
- SepsisPhase 2
- Acute respiratory distress syndromePhase 2
- Cutaneous squamous cell carcinomaPhase 2
- Granulomatosis with polyangiitisPhase 2
- Hidradenitis suppurativaPhase 2
- Microscopic polyangiitisPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2109636, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 11346, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Vilobelimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 1 product on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: GohibicEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Vilobelimab
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
NCT06701682 · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
|
Phase 2 | Recruiting | PPD Development, LP | USA |
|
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
NCT06703073 · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
|
Phase 2 | Recruiting | PPD Development, LP | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Vilobelimab across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
1 single-substance product containing Vilobelimab on the HPRA medicines list.
- Gohibic 200 mg Concentrate for solution for infusionInflaRx GmbH · EU/1/24/1884/001
Supply shortages
No entry for Vilobelimab in the EMA, FDA or German BfArM shortage lists we track.
Conditions studied with Vilobelimab
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| PPD Development, LP | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Vilobelimab trials
How many clinical trials are testing Vilobelimab?
2 current trials in our USA register name Vilobelimab as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Vilobelimab trials recruiting patients?
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Vilobelimab clinical trials?
The lead sponsor is PPD Development, LP. The number in brackets is how many trials each organisation leads.
Is Vilobelimab licensed in Ireland?
Yes. The HPRA medicines list includes 1 single-substance product containing Vilobelimab, for example Gohibic 200 mg Concentrate for solution for infusion (InflaRx GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Vilobelimab shortage?
Not in the lists we track: Vilobelimab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Vilobelimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Vilobelimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Vilobelimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.